Company Data

Merck Total Revenue (Oncology) - Global

(in million U.S. dollars)

Description

Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.

Oncology Portfolio: #1 COMPANY IN ONCOLOGY PRODUCT SALES.

  • Keytruda - WORLD’S LARGEST SELLING DRUG
  • Welireg
  • Lynparza (collaboration with AstraZeneca)
  • Lenvima (collaboration with Eisai)
  • Reblozyl (Bristol Myers Squibb Company)

Revenue (2024):

  • Worldwide sales were $64.2 billion in 2024, an increase of 7% compared with 2023 ($60.1 billion)
  • Global sales growth was primarily due to higher sales in the oncology franchise, largely due to strong growth of Keytruda and Welireg, as well as increased alliance revenue from Reblozyl and Lynparza. Sales of Keytruda ($29.482 billion) represented 46% of the Company's total sales.

Research and Development Update:

The Company is diversifying its oncology portfolio and executing on its strategy which is broadly based on three strategic pillars: immuno-oncology, precision molecular targeting and tissue targeting.

  • Last Updated Date : 22 Jul 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Merck & Co., Inc (ANNUAL REPORT FORM 10-K)
  • Competitors : Roche; Bristol-Myers Squibb Company; AstraZeneca; Johnson & Johnson; Pfizer; Novartis
Bristol-Myers Squibb Total Revenue (Oncology) - Global

(in million U.S. dollars)

Description

Bristol-Myers Squibb is a specialty biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb focuses on core therapeutic areas: (1) oncology with a priority in certain tumor types; (2) immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease; (3) cardiovascular with a priority in heart disease and (4) fibrotic disease with priorities in lung and liver. 

#2 COMPANY IN ONCOLOGY PRODUCT SALES. 

Oncology Portfolio: Key Marketed Products - Bristol-Myers Squibb maintains an extensive oncology portfolio for patients with solid tumors and haematological cancers. 

  • ABECMA®
  • ABRAXANE®
  • AUGTYRO™
  • BREYANZI®
  • EMPLICITI®
  • INREBIC®
  • KRAZATI®
  • ONUREG®
  • OPDIVO®
  • OPDUALAG™
  • POMALYST®
  • REVLIMID®
  • SPRYCEL®
  • THALOMID®
  • VIDAZA®
  • YERVOY®

Revenue (2024):

  • Worldwide total revenues were $48.3 billion, up by 7% (2023: $ 45.0 billion) driven by the Growth Portfolio (Opdivo, Yervoy, Opdualag, Breyanzi, Abecma, Krazati); partially offset by generic erosion in the Legacy Portfolio (Revlimid, Sprycel, Abraxane)
  • Worldwide net sales in the oncology therapeutic area were $26 billion.
  • Opdivo: U.S. revenues increased 2% in 2024 primarily due to higher average net selling prices, partially offset by lower demand. International revenues increased 5% in 2024 primarily due to higher demand for core indications and additional indication launches and higher average net selling prices, partially offset by foreign exchange impact of 9%. Excluding foreign exchange impacts, revenues increased 14%.
  • Yervoy: U.S. revenues increased 16% in 2024 primarily due to higher demand and higher average net selling prices. International revenues increased 8% in 2024 primarily due to higher demand as a result of additional indication launches and core indications, partially offset by foreign exchange impacts of 7%. Excluding foreign exchange impacts, revenues increased 15%.
  • Breyanzi: U.S. revenues increased 95% in 2024 primarily due to higher demand enabled by expanded manufacturing capacity, new indication launches and higher average net selling prices. International revenues increased 156% in 2024 primarily due to higher demand, partially offset by foreign exchange of 6%. Excluding foreign exchange impacts, revenues increased 162%.
  • Abecma: U.S. revenues decreased 32% in 2024 primarily due to increased competition in BCMA targeted therapies. International revenues increased 44% in 2024 due to higher demand partially offset by foreign exchange of 3%. Excluding foreign exchange impacts, revenues increased 47%.
  • Revlimid: U.S. revenues decreased 4% in 2024 primarily due to generic erosion and lower average net selling prices partially offset by the prior year impact of patients receiving free drug product from the Bristol Myers Squibb Patient Assistance Foundation, a separate and independent 501(c)(3) entity to which BMS donates products. International revenues decreased 14% in 2024 primarily due to generic erosion across several European countries and foreign exchange impacts of 3%. Excluding foreign exchange impacts, revenues decreased 11%. In the U.S., certain third parties have been granted volume-limited licenses to sell generic lenalidomide. Pursuant to these licenses, several generics have entered or are expected to enter the U.S. market with volume-limited quantities of generic lenalidomide. These licenses will no longer be volume limited beginning on January 31, 2026. In the EU and Japan, generic lenalidomide products have entered the market.
  • Sprycel: U.S. revenues decreased 31% in 2024 primarily due to lower average net selling prices and lower demand driven by generic erosion. International revenues decreased 40% in 2024 primarily due to lower demand driven by generic erosion, lower average net selling prices and foreign exchange impact of 4%. Excluding foreign exchange impact, revenues decreased 36%. In the U.S. (September 2024) and EU, generic dasatinib products have entered the market. In Japan, the composition of matter patent for the treatment of non-imatinib-resistant CML has expired.
  • Abraxane: U.S. revenues decreased 23% in 2024 primarily due to lower demand driven by generic erosion

 Bristol-Myers Squibb 2025 guidance:

  • Total Revenue range of ~$46.5 billion to $47.5 billion reflecting the strength of the Growth Portfolio
  • Continued generic erosion within Legacy Portfolio in 2025 primarily due to Revlimid, Sprycel, and for Pomalyst outside the U.S.

  • Last Updated Date : 30 Jan 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Bristol-Myers Squibb (ANNUAL REPORT & Form 10-K), Investor & Earnings Presentation
  • Competitors : Merck & Co., Inc.; Roche; AstraZeneca; Johnson & Johnson; Pfizer
Roche Total Revenue (Oncology) - Global

(in million Swiss Franc)

Description

Roche is one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. A global pioneer in pharmaceuticals and diagnostics. #1 in Neurology, #3 in Oncology & leader in Ophthalmology. Roche focuses on five core therapeutic areas (Pharmaceuticals Division)— Oncology/Haematology, Immunology, Neurology, Ophthalmology and Cardiovascular/Renal/Metabolism. 

Oncology Portfolio (Pharmaceuticals Division): Key Marketed Products:

  • Tecentriq
  • Perjeta
  • Kadcyla
  • Phesgo
  • Alecensa
  • Herceptin
  • Avastin
  • Erivedge
  • MabThera/Rituxan
  • Polivy
  • Gazyva/Gazyvaro
  • Columvi

Revenue (2024):

  • Worldwide sales in the Pharmaceuticals Division were CHF 46.2 billion (2023: CHF 44.3 billion), an increase of 8% at CER.
  • Full-Year Global Net Revenues from the Oncology Portfolio were CHF 19.241 billion (2023: CHF 19.087 billion).
  • Sales in the oncology/haematology therapeutic area increased by 7%, with the growth being driven by Phesgo, Hemlibra and Polivy, partially offset by the biosimilar competition for Avastin, Herceptin and MabThera/Rituxan.
  • In oncology, Tecentriq sales were flat at CHF 3.6 billion, with the growth in the international region and in Europe being offset by a decrease in the US due to continued pressure from competition.
  • Sales of Perjeta were CHF 3.6 billion, an increase of 1% due to higher sales in the International region, while in the US the lower sales resulting from the conversion to Phesgo were more than offset by the base effect of an adjustment made in 2023 related to the reserves for US governmental plans.
  • Sales of Phesgo were CHF 1.7 billion, showing a growth of 62%.
  • Polivy sales increased by 39% to CHF 1.1 billion, notably in the US. 

2025 Guidance:

  • Pharma sales growth : 10%
  • Young portfolio to drive growth in the near- to mid-term
  • Two NME approvals expected for 2024: PiaSky (crovalimab) in PNH1 and inavolisib in HR+ breast cancer

  • Last Updated Date : 28 Jan 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : ROCHE (ANNUAL REPORT, FINANCE REPORT), Investor Presentation
  • Competitors : Merck & Co., Inc. ; Bristol-Myers Squibb Company; AstraZeneca; Johnson & Johnson; Pfizer; Novartis
AstraZeneca Total Revenue (Oncology) - Global

(in million U.S. dollars)

Description

AstraZeneca is a global, science-led, patient-focused pharmaceutical company. AstraZeneca focuses on core therapeutic areas: Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I) and Vaccines & Immune Therapies (V&I)); and Rare Disease. 

#4 COMPANY IN ONCOLOGY PRODUCT SALES.

Oncology Portfolio: Key Marketed Products - AstraZeneca maintains an extensive oncology portfolio for patients with solid tumors and haematological cancers. (Key disease areas: Lung cancer, Breast cancer, Ovarian cancer, Prostate cancer, Blood Cancer, Liver cancer, Pancreatic cancer)

  • Tagrisso
  • Lynparza - strategic oncology collaboration with MSD
  • Calquence
  • Imfinzi
  • Enhertu - alliance with Daiichi Sankyo to develop and commercialize Enhertu
  • Zoladex
  • Truqap
  • Imjudo
  • Orpathys
  • Datroway - jointly developed and commercialized with Daiichi Sankyo.

 Revenue (2024):

  • Worldwide sales were $54.1 billion* in 2024, an increase of 18% at actual rate of exchange, comprising Product Sales of $50,938 million (up 16%; 19% at CER), Alliance Revenue of $2,212 million (up 55%; 55% at CER) and Collaboration Revenue of $923 million (up 56%; 54% at CER) compared with 2023 ($45.81 billion*).
  • Worldwide Oncology sales were $22.353 billion* (41% Total Revenue) in 2024 an increase of 21% (24% at CER) compared with 2023 ($18.447 billion*). Commercial delivery and sales performance driven by five multiblockbuster medicines in 2024: Tagrisso ($6.580 billion), Imfinzi ($4.717 billion), Calquence ($3.129 billion), Lynparza ($3.672 billion) and Enhertu ($1.982 billion).
  • Worldwide Oncology Product sales were $20.275 billion in 2024. 

* Total Revenue consists of Product Sales, Alliance Revenue and Collaboration Revenue

Long Term Outlook:

  • Total Revenue in 2025 anticipated to increase by a high single-digit percentage. Double-Digit growth in Oncology in 2025
  • By 2030, AstraZeneca aims to launch 20 new medicines and achieve $80 billion in Total Revenue with sustained growth thereafter.

  • Last Updated Date : 06 Feb 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : AstraZeneca (ANNUAL REPORT & Form 20-F), Investor Presentation, J.P. Morgan Healthcare Conference
  • Competitors : Merck & Co., Inc.; Bristol-Myers Squibb Company; Roche; Johnson & Johnson; Pfizer
Johnson & Johnson Total Revenue (Oncology) - Global

(in million U.S. dollars)

Description

Johnson & Johnson and its subsidiaries (the Company) is engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Company is organized into two business segments: Innovative Medicine and MedTech. 

#5 COMPANY IN ONCOLOGY PRODUCT SALES.

Oncology Portfolio (Innovative Medicine): Johnson & Johnson maintains an extensive oncology portfolio (e.g., multiple myeloma, prostate cancer, hematologic malignancies, lung cancer and bladder cancer). 

  • DARZALEX®
  • ERLEADA®
  • IMBRUVICA®
  • CARVYKTI®
  • ZYTIGA /abiraterone acetate
  • TECVAYLI
  • AKEEGA®
  • BALVERSA®
  • LAZCLUZE™
  • PROCRIT®
  • RYBREVANT®
  • TALVEY™
  • VENTAVIS®
  • YONDELIS®

 Revenue (2024):

  • Innovative Medicine segment sales in 2024 were $57.0 billion, an increase of 4.0% from 2023 ($54.75 billion), which included operational growth of 5.7% and a negative currency impact of 1.7%.
  • Full-Year Global Net Revenues from the Oncology Portfolio were $20.781 billion in 2024, Increase of 17.7 Percent as compared to 2023 ($17.661 billion).
  • Sales of Johnson & Johnson’s largest product, collectively DARZALEX (daratumumab) and subcutaneous (SC) product DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 13.1% of the Company's total revenues for fiscal 2024. DARZALEX sales increased by 19.8%. $11.670 billion (2023: $9.744 billion) driven by continued share gains and market growth.
  • Sales of CARVYKTI were driven by continued share gains, capacity expansion and manufacturing efficiencies. CARVYKTI sales increased by 92.7 %. $963 million (2023: $500 million)
  • Additionally, sales from the ongoing launches of TECVAYLI, TALVEY and RYBREVANT included in Other Oncology, contributed to the growth.
  • Growth was partially offset by ZYTIGA due to loss of exclusivity and IMBRUVICA due to global competitive pressures.

Long-Term Guidance:

  • Johnson & Johnson aims to grow oncology sales to $50 billion by 2030
  • 35+ planned approvals/filings through 2030

  • Last Updated Date : 05 Mar 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Johnson & Johnson (ANNUAL REPORT FORM 10-K), Earnings Presentation, J.P. Morgan Healthcare Conference
  • Competitors : Merck & Co., Inc.; Bristol-Myers Squibb Company; Roche; AstraZeneca;; Pfizer; Novartis
Pfizer Total Revenue (Oncology) - Global

(in million U.S. dollars)

Description

Pfizer Inc. is a research-based, global biopharmaceutical company involved in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Pfizer manages its commercial operations through a global structure consisting of three operating segments: Biopharma, PC1, and Pfizer Ignite. Among these, Biopharma is the only reportable segment. In 2024, the commercial structure within the Biopharma reportable segment included the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. 

#6 COMPANY IN ONCOLOGY PRODUCT SALES.

Oncology includes:

  • Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer.
  • Oncology biosimilars

Oncology Portfolio: Key Marketed Products:

  • Ibrance – Top Selling Oncology Drug
  • Xtandi - developed and commercialized in collaboration with Astellas
  • Padcev - co-developed and jointly commercialized with Astellas
  • Adcetris - developed and commercialized in collaboration with Takeda
  • Inlyta
  • Lorbrena
  • Bosulif
  • Braftovi/Mektovi
  • Tukysa
  • Elrexfio
  • Tivdak
  • Talzenna
  • Oncology biosimilars (Retacrit, Ruxience, Zirabev, Trazimera and Nivestym)

 Revenue (2024):

  • Worldwide sales were $ 63.6 billion in 2024, an increase of 7% compared with 2023 ($59.6 billion)
  • Full-Year Global Net Revenues from the Oncology Portfolio were $15.612 billion in 2024, an increase of 31.45 Percent as compared to 2023 ($12.450 billion).
  • Increase in revenues from legacy Seagen, which was acquired in December 2023 (Padcev, Adcetris)
  • Worldwide growth from the Vyndaqel family, Eliquis, Xtandi and Nurtec ODT/Vydura, partially offset by declines from Xeljanz, Ibrance, Abrysvo, Inlyta and the Prevnar family.
  • Decline in oncology biosimilars, largely due to lower net price in the U.S.
  • Xtandi (3% contribution of total revenue in 2024) sales in the United States increased by 23% 2024: $2.039 billion (2023: $1.659 billion). Growth largely driven by strong demand due to uptake of the nmCSPC indication following approval in the fourth quarter of 2023 and increased affordability in the U.S.
  • Ibrance (7% contribution of total revenue in 2024) Global sales decreased by 8% 2024: $4.367 billion (2023: $4.753 billion). Declines primarily driven by lower demand due to competitive pressures mainly in the U.S., price decreases in certain international developed markets and generic penetration in certain emerging markets.

2025 revenue guidance: Key Product Assumptions and Considerations

  • The company anticipates 2025 revenue to be in the range of $61.0 to $64.0 billion.
  • Seagen impact: Overall growth rate mathematically dampened due to overlapping of Seagen acquisition.
  • Padcev: benefit from continued uptake in 1L la/mUC.
  • Lorbrena: expected to continue to benefit from share expansion into 1L treatment and long duration of therapy
  • Ibrance: competitive pressures across markets as well as generic entry in select markets.
  • Elrexfio: U.S. - Continued growth due to anticipated increase in overall share and new patient starts within the BCMA BsAb class; International - Continued growth driven by significant and rapid demand in Japan and other countries where Elrexfio was first-to-market or launched simultaneously with competition, as well over 20 additional anticipated approvals and/or commercially reimbursed launches.

  • Last Updated Date : 06 Feb 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Pfizer Inc. (ANNUAL REPORT FORM 10-K), Earnings Presentation, J.P. Morgan Healthcare Conference
  • Competitors : Merck & Co., Inc.; Bristol-Myers Squibb Company; Roche; AstraZeneca; Johnson & Johnson; Novartis

Have questions about how our healthcare intelligence solutions can empower your organization?

up